TY  - JOUR
AU  - Newsome, Philip N
AU  - Buchholtz, Kristine
AU  - Cusi, Kenneth
AU  - Linder, Martin
AU  - Okanoue, Takeshi
AU  - Ratziu, Vlad
AU  - Sanyal, Arun J
AU  - Sejling, Anne-Sophie
AU  - Harrison, Stephen A
AU  - NN9931-4296 Investigators
PY  - 2020
DO  - 10.1056/NEJMoa2028395
UR  - https://hdl.handle.net/10668/26681
T2  - The New England journal of medicine
AB  - Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with...
LA  - en
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Amylases
KW  - Biopsy
KW  - Diabetes Mellitus, Type 2
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Female
KW  - Glucagon-Like Peptides
KW  - Humans
KW  - Injections, Subcutaneous
KW  - Lipase
KW  - Liver
KW  - Liver Cirrhosis
KW  - Male
KW  - Middle Aged
KW  - Non-alcoholic Fatty Liver Disease
KW  - Young Adult
TI  - A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
TY  - research article
VL  - 384
ER  -